News Search Results

We are thrilled to share that 71 Swedish-affiliated providers are included in Seattle Met’s 14th annual list of 2019 Top Doctors. Voters nominated their most esteemed peers based on years of experience, competency, rapport with patients, patient satisfaction and compliance with care recommendations and ability to work effectively with colleagues across specialties to deliver the best patient care.

Swedish today published its 2018 Community Benefit Report, detailing the organization’s more than $237 million investment in community benefit programs for the year, including $23.8 million in free and discounted care. In the last six years, Swedish has invested more than $1.1 billion in community benefit.

There are currently multiple cases of measles in several western Washington counties. Transmission of measles can occur before people know they have the disease, before any rash appears. Before the measles diagnosis was made, infected individuals were in several public locations. To find out more about measles, these exposure locations, and what to do if you may have been exposed visit Public Health - Seattle & King County.

Swedish Cancer Institute Center for Blood Disorders and Stem Cell Transplantation achieves accreditation from the Foundation for the Accreditation of Cellular Therapy

Through new HIPAA-compliant skills, users will be able to set up health care visits and manage medical appointments using their voice on any Alexa-enabled device.

Swedish today announced that Dr. Kristen M. Swanson, dean of the College of Nursing at Seattle University and a Swedish Board of Trustees member since January 2015, is the new chair of the board. Dr. Swanson succeeds Dr. Michael J. Hart.

Mental health, drug addiction and homelessness emerged as major issues in our communities.

Swedish today announced a partnership with One Medical, the leading member-based, technology-enabled modern primary care provider. This partnership with One Medical provides Swedish the opportunity to expand its reach in the community while offering patients continuity of care if they need to access specialty and hospital care at Swedish.

Low and intermediate-risk prostate cancer patients treated with CyberKnife had a disease-free survival rate of 97.3 and 97.1 percent five years after treatment.

We are excited to announce Swedish Ballard received the Pathway to Excellence® re-designation from the American Nurses Credentialing Center (ANCC). Swedish Ballard was the first hospital to be designated as a Pathway to Excellence Organization in 2015.